An Open-Label, Multicentre, Phase 1 Clinical Study to Evaluate the Safety and Efficacy of Zorifertinib Combined With Osimertinib in Patients With Advanced Non-Small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment

This is a clinical trial that aims to test Zorifertinib when used together with a known drug, Osimertinib. The goal is to learn if this combination is safe and works for people with advanced Non-Small Cell Lung Cancer (NSCLC) whose cancer has spread to the membranes surrounding the brain and spinal cord (a condition called leptomeningeal metastases) after being treated with Osimertinib.

开始日期2026-01-31

申办/合作机构

江苏晨泰医药科技有限公司

NCT07143045

/ RecruitingN/A

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

This study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS metastases, and to compare the clinical value of zorifertinib with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).

开始日期2025-12-29

申办/合作机构

江苏晨泰医药科技有限公司

100 项与盐酸佐利替尼相关的临床结果

登录后查看更多信息

100 项与盐酸佐利替尼相关的转化医学

登录后查看更多信息

100 项与盐酸佐利替尼相关的专利（医药）

登录后查看更多信息

项与盐酸佐利替尼相关的文献（医药）

2026-04-05·CHINESE MEDICAL JOURNAL

Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997–2026)

Review

作者: Han, Xiaohong ; Yang, Mengwei ; Xie, Zucheng ; Gao, Ruyun ; Sun, Yan ; Chen, Xinrui ; Shi, Yuankai

Abstract:

Epidermal growth factor receptor ( EGFR ) is a critical driver gene in non-small cell lung cancer (NSCLC). Since 1997, EGFR tyrosine kinase inhibitors (EGFR-TKIs) have evolved from first-generation agents, such as gefitinib, erlotinib, and icotinib, to second-generation agents like afatinib and dacomitinib, now to third-generation agents, including osimertinib, aumolertinib, furmonertinib, befotertinib, rezivertinib, rilertinib, limertinib, lazertinib, mifanertinib for EGFR L858R, sunvozertinib for EGFR exon 20 insertion (20ins), and zorifertinib for EGFR -sensitive mutation with brain metastases. Throughout this evolution, EGFR-TKIs have become the cornerstone of treatment for EGFR -mutant NSCLC, extending beyond advanced stages to encompass the entire disease spectrum, including perioperative and maintenance therapies, with combination therapies further expanding treatment options. These advancements have significantly improved patient survival and quality of life. However, challenges such as acquired resistance remain significant hurdles in achieving long-term disease control. Over the past 30 years, substantial advancements have been made in the comprehensive management of EGFR -mutant NSCLC. This systemic review provides the history of the development of EGFR-TKI therapy for NSCLC from 1997 to 2026, highlighting clinical milestones, emerging therapies, and future directions in this rapidly evolving field.

2026-04-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Subtype-specific APOBEC enrichment links genomic instability to predict immunotherapy response in breast cancer subtypes

Article

作者: Zhou, JiaQi ; Cao, XuChen ; Ning, ChunLan ; Zhao, ZeWei ; Xie, Yongjie ; Yu, Yue ; Wang, Xin ; Jia, WenBin ; Zhou, Yaoyao

Breast cancer (BRCA), a prevalent malignancy among women, significantly impacts survival quality and life expectancy, with rising incidence and mortality rates posing substantial psychological and economic burdens on patients and families. Current treatment modalities exhibit considerable variability in efficacy, often hindered by resistance and recurrence, thus emphasizing the urgent need for novel biomarkers and therapeutic targets. This study investigates the genomic characteristics of the APOBEC family genes across different BRCA subtypes and their influence on mutation profiles. Utilizing data from multiple databases, including The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), SMC, and Metabric, we conducted a comprehensive analysis of APOBEC mutation enrichment scores (APMs) and tumor mutational burden (TMB). Our findings reveal that APMs are significantly elevated in BRCA compared to other cancers, with distinct variations among subtypes; specifically, HER2⁺ breast cancer exhibited the highest APMs while triple-negative breast cancer (TNBC) displayed the lowest. We also observed correlations between APMs and TMB, suggesting differential immune microenvironment interactions, particularly in HER2⁺ versus TNBC and Luminal subtypes. Furthermore, APMs demonstrated a significant association with DNA damage response pathways, with implications for treatment strategies. Our study subsequently investigates the predictive role of the APOBEC mutagenesis-related prognostic risk score (AMrs) in guiding targeted and immunotherapy combinations for different subtypes of BRCA, specifically TNBC, Luminal, and HER2⁺ breast cancer. By leveraging a multi-center database, we seek to validate the correlation between AMrs scores and the sensitivity of these BRCA subtypes to immunotherapy. Based on in vivo experiments in mice, our research highlights that the administration of specific agents-AZD3759 for HER2+, Vorinostat for TNBC, and SGC0946 for Luminal-when combined with anti-PD-1 therapy, not only boosts therapeutic effectiveness but also transforms the immunological environment within tumors. This synergistic approach led to notable reductions in tumor volume and an increase in cytotoxic T cell density in in vivo and in vitro experiments, further validating the role of AMrs scores in tailoring treatment modalities across BRCA subtypes. Overall, our study elucidates the critical role of APOBEC family genes in BRCA heterogeneity, highlighting their potential as biomarkers for personalized therapeutic approaches and pointing towards future research directions in integrating APOBEC-related mechanisms with immunotherapy.

2026-03-06·Gut and Liver

Identification of Poor Prognosis-Associated Fibroblast Subpopulation Signature Genes Utilizing the Scissor Algorithm to Classify Colorectal Cancer Subtypes and Evaluate the Immune Landscape

Article

作者: Zhang, Jie ; Gu, Jianhui ; Wen, Xing ; Wang, Meng

Background/Aims:

Colorectal cancer (CRC) shows high heterogeneity. Conventional bulk transcriptome-based classification methods fail to capture the complex tumor microenvironment of CRC, limiting precision therapy advances. The Scissor algorithm integrates single-cell/bulk transcriptomic data with clinical information to identify prognosis-linked cell subpopulations, offering new insights into tumor heterogeneity resolution.

Methods:

We integrated bulk RNA-seq data, single-cell RNA-seq data, and clinical information from The Cancer Genome Atlas and Gene Expression Omnibus databases. The Scissor algorithm was employed to screen fibroblast subpopulations strongly associated with prognosis. Multidimensional analyses, including signature gene identification, functional enrichment analysis, Gene Set Variation Analysis (GSVA)-based subtyping, survival analysis, immune landscape assessment, cell-cell communication, mutational profiling, and drug sensitivity prediction, were conducted.

Results:

We identified Scissor+ fibroblast subpopulations significantly correlated with prognosis, whose signature genes were associated with pro-metastatic pathways such as extracellular matrix remodeling and transforming growth factor-beta signaling. GSVA scoring stratified samples into Scissor_high and Scissor_low subtypes, with the former being associated with worse survival outcomes, immunosuppressive microenvironment features (including Treg and M2 macrophage enrichment), and stronger immune evasion tendencies. Cell communication analysis revealed that the Scissor_high subtype strongly interacted with many cell types, with remarkable enrichment in the ANNEXIN, SPP1, and NIF signaling pathways. Drug sensitivity predictions suggested that patients with this cell subtype may respond better to specific anticancer agents (e.g., AZD3759, Erlotinib, Gefitinib).

Conclusions:

This study was the first to identify Scissor+ fibroblast subpopulations markedly associated with poor prognosis in CRC, revealing their ability to activate pro-metastatic pathways and immune-activated but functionally exhausted characteristics. Moreover, their predictive value in CRC therapy was revealed. The study provided new perspectives for CRC prognosis evaluation and personalized immune-targeted combination therapies.

141

项与盐酸佐利替尼相关的新闻（医药）

2026-04-23

·药策论讯

2026.04.23药品注册审评及批准件及不批准通知件概况

报告日期：2026年4月23日（星期四）数据来源：国家药品监督管理局(NMPA)、药品审评中心(CDE) 一、注册受理品种 1. GenSci144片表格项目详情受理号CXHL2600475、CXHL2600476企业名称长春金赛药业有限责任公司申请类型境内生产药品注册临床试验注册分类化药1类适应症苯丙酮尿症(PKU)来源网站NMPA/CDE 同品种上市企业： SLC6A19抑制剂为创新靶点，目前中国尚无同品种上市药品全球范围内，大冢制药的JNT-517(Repinatrabit)正在美国进行PKU的3期临床试验在申报受理企业量：中国：仅金赛药业1家申报临床 2. 吡美莫司乳膏表格项目详情受理号CYHS2600929企业名称山西泽辰医药科技有限公司（联合申报：湖南九典制药股份有限公司）申请类型仿制注册分类4类来源网站CDE 同品种已上市企业：表格企业名称备注晖致医药有限公司原研进口，商品名：爱宁达(Elidel)江苏吴中医药集团有限公司苏州制药厂2026年4月获批上市江苏知原药业有限公司国产仿制海南元盈医药有限公司国产仿制海南皇隆制药股份有限公司国产仿制在申报受理企业量：软膏剂领域，吡美莫司乳膏报产在审企业约10家2025年全国医院销售额约2.85亿元 3. 甘糖酯片表格项目详情受理号CXHL2600484企业名称青岛国信制药有限公司申请类型新药注册分类2.4类（改良型新药）适应症高脂血症来源网站CDE 同品种已上市企业：表格企业名称备注青岛国信制药有限公司(正大制药青岛)上市许可持有人青岛海大科技制药有限公司50mg规格在申报受理企业量：目前暂无其他企业申报二、药品批准证明文件送达信息批准日期：2026年4月21-22日（部分品种）化学药品（补充申请/仿制药）表格受理号药品名称申请人批准日期CYHB2401107马来酸依那普利叶酸片深圳奥萨制药有限公司2026-04-21CYHB2401108马来酸依那普利叶酸片深圳奥萨制药有限公司2026-04-21CYHB2402237盐酸佐利替尼片江苏晨泰医药科技有限公司2026-04-22CYHB2402238盐酸佐利替尼片江苏晨泰医药科技有限公司2026-04-22CYHB2450628西咪替丁片万邦德制药集团有限公司2026-04-22CYHB2500210盐酸倍他司汀片森淼（山东）药业有限公司2026-04-21CYHB2501247布美他尼注射液四川美大康华康药业有限公司2026-04-21CYHB2502530维生素C注射液武汉久安药业有限公司2026-04-21CYHB2550213醋酸地塞米松片天津力生制药股份有限公司2026-04-21CYHB2600087奥沙利铂注射液江苏恒瑞医药股份有限公司2026-04-21CYHB2600088福多司坦片四川科伦药业股份有限公司2026-04-21CYHB2600090甲钴胺片山东新华制药股份有限公司2026-04-21CYHB2600107注射用阿奇霉素东药集团沈阳施德药业有限公司2026-04-21CYHB2600127磷酸奥司他韦胶囊博瑞制药（苏州）有限公司2026-04-21CYHB2600139苯甲酸阿格列汀片宁波美诺华天康药业有限公司2026-04-22CYHB2600140苯甲酸阿格列汀片宁波美诺华天康药业有限公司2026-04-22CYHB2600152普瑞巴林口服溶液贝克诺顿（浙江）制药有限公司2026-04-22CYHB2600620氯化钾颗粒山东新华制药股份有限公司2026-04-21CYHB2600630硫酸阿米卡星注射液哈药集团生物工程有限公司2026-04-21CYHB2600631硫酸阿米卡星注射液哈药集团生物工程有限公司2026-04-21 生物制品表格受理号药品名称申请人批准日期CYSB240016123价肺炎球菌多糖疫苗北京民海生物科技有限公司2026-04-22CYSB2400224甘精胰岛素注射液甘李药业股份有限公司2026-04-22CYSB2500025流感病毒裂解疫苗长春生物制品研究所有限责任公司2026-04-22CYSB2500026流感病毒裂解疫苗长春生物制品研究所有限责任公司2026-04-22 中药表格受理号药品名称申请人批准日期CYZB2501675周氏回生丸北京同仁堂股份有限公司同仁堂制药厂2026-04-21CYZB2502730参桂理中丸北京同仁堂股份有限公司同仁堂制药厂2026-04-21CYZB2502731参桂理中丸北京同仁堂股份有限公司同仁堂制药厂2026-04-21CYZB2600286仙方活命片广东万年青制药股份有限公司2026-04-21CYZB2600295乙肝解毒胶囊广东雷允上药业有限公司2026-04-21CYZB2600296乙肝扶正胶囊广东雷允上药业有限公司2026-04-21CYZB2600300清热解毒口服液河南华雒康润药业有限公司2026-04-21CYZB2600319八珍丸成都地奥集团天府药业股份有限公司2026-04-21CYZB2600320八珍丸成都地奥集团天府药业股份有限公司2026-04-21CYZB2600321复方木鸡合剂丹东药业集团有限公司2026-04-21CYZB2600323复方木鸡颗粒丹东药业集团有限公司2026-04-21 进口药品表格受理号药品名称申请人批准日期JTH2600065舒洛地特软胶囊阿尔法西格玛（北京）医药咨询有限公司2026-04-21JTH2600069舒更葡糖钠注射液默沙东研发（中国）有限公司2026-04-21JTH2600070利福昔明对照品阿尔法西格玛（北京）医药咨询有限公司2026-04-21JYHB2500336艾曲泊帕乙醇胺片北京诺华制药有限公司2026-04-21JYHB2500696环硅酸锆钠散阿斯利康投资（中国）有限公司2026-04-22JYHB2500697环硅酸锆钠散阿斯利康投资（中国）有限公司2026-04-22JYHB2500723注射用甲泼尼龙琥珀酸钠辉瑞投资有限公司2026-04-22JYHZ2500259盐酸氮䓬斯汀滴眼液晖致医药有限公司2026-04-21 三、药品不批准通知件送达信息表格受理号药品名称申请人签发日期CYHB2500131葡萄糖注射液安徽双鹤药业有限责任公司2026-04-22CYSB2600023注射用瑞康曲妥珠单抗苏州盛迪亚生物医药有限公司2026-04-22 四、本日审评摘要受理情况临床试验申请受理：1个（GenSci144片，PKU创新药）仿制药申请受理：1个（吡美莫司乳膏）新药申请受理：1个（甘糖酯片，2.4类改良型新药）批准情况化学药品：20个批准（含补充申请、一致性评价等）生物制品：4个批准（疫苗、胰岛素等）中药：11个批准进口药品：8个批准

2026-04-13

·有驾

华鑫证券发布最新研究报告：建议给予西藏药业买入评级

华鑫证券的分析师胡博新与吴景欢近期对西藏药业进行了调研，并给出买入评级。这家公司在2025年交出了一份营收增长、利润波动的成绩单。西藏药业2025年总收入达到29.82亿元，涨幅为6.23%。归属于母公司的净利润为9.38亿元，比前一年少了10.78%。不过，扣除掉那些非经常性损益后，公司的净利润实际上微增了1.48%，达到8.71亿元。公司的现金流表现比较稳健，经营性现金流净额为10.05亿元，小幅增长了1%。公司目前的业绩增长点依然在存量业务上。核心产品新活素是收入的大头，销售额达到25.65亿元，在总收入里占比超过八成。去年新活素卖出了734.59万支，销量稳步提升。为了应对市场需求，公司专门升级了新活素的生产线。随着这条新生产线的投产，年产能提升到了1500万支，为后续的销售提供了保障。公司在分红方面一直很慷慨。 2025年，公司拿出净利润的六成用于现金分红，派发了5.63亿元的现金红利。这已经是公司连续保持高比例分红了。目前公司账上躺着23.3亿元的现金和11.2亿元的金融资产，资金储备非常充裕。除了稳住基本盘，公司也在积极寻找未来的增长点，重点放在了创新药研发上。公司先后投资了锐正基因和晨泰医药。锐正基因主要研究基因编辑技术，他们研发的针对心肌病和神经病变的产品正在进入临床二期阶段。在胆固醇管理方面，他们的另一个项目也在进行临床研究。对于晨泰医药，西藏药业不仅入股，还拿下了他们旗下佐利替尼的独家销售权。目前这款药已经进入了医保目录，市场空间值得期待。从长远来看，机构对西藏药业的增长前景持乐观态度。分析师预计公司未来三年的收入和利润将保持增长。以目前的股价计算，公司的市盈率水平并不高。当然，医药行业的竞争很激烈，研发进展和集采政策都可能对业绩产生影响，这些都是投资者需要留意的风险点。

2026-04-12

·百度百家

西藏药业潜力大，投资机会来了，华鑫证券推荐买入

从“新活素”到基因编辑西藏药业的再生逻辑西藏药业的2025年年报看似平稳，实则暗藏一个“增长拐点”。营收29.82亿元，同比增6.23%；归母净利虽降10.78%，但扣非净利仍涨1.48%，账上现金超过23亿元。数字不炸眼，却透露出一种节制后的冲劲。这家曾以生物制药起家的公司，正在用一种更大的逻辑——“第二曲线”自我重塑。新活素依然是利润中枢，贡献86%的收入，占据几乎全部重心。这个由公司深耕多年的血液制品，在2025年卖出734.59万支，同比增4.82%，产能也正通过冻干车间B线的启用进一步扩张。稳定的现金流和居高的分红（红利占净利六成，并连续两年维持）让它看起来更像一个稳健“现金奶牛”。但问题恰恰在这里——太稳的业务往往意味着增长余地有限。公司押注了两个方向锐正基因和晨泰医药。前者代表未来五到十年的尖端生物技术——体内基因编辑。锐正基因的ART001已进入临床II期，用于治疗罕见的ATTR-PN；而ART002聚焦降脂新靶点PCSK9，临床研究已启动。这类技术不只是药，更可能成为疾病治理方式的重构。投资6000万美元，公司换来的是一张技术门票，也是一张时间通行证。另一个方向更具现实意义——通过3亿元参股晨泰医药，代理其已上市的靶向药“佐利替尼”。这是立刻能落地的生意，疗效清晰，政策支持明确，还叠加进入医保目录的市场催化。此举让公司实现了“利润现金流+渠道整合”的双向补充，开始像一家兼顾科研与商业的复合型制药企业。如果拆开西藏药业的这两步棋分别对应了药企创新周期的两端。一端是现金流守护者，为创新提供燃料，一端是技术孵化器，为未来积蓄动能。这是典型的“系统再生”战略让旧系统供血，新系统试错。只有这样，才可能跨越从“药”到“疗”的范式更迭。创新不等于立刻收益。基因编辑药物仍面临巨大的技术壁垒和监管审查。实验室的突破，不一定能快速转化为临床利润。风险提示里提到的“研发进展不及预期”，并非套话，而是现实。如何平衡短期财务稳健与长期创新押注，将考验管理层的定力。值得注意的是，西藏药业这种“双系统结构”在医药史上并非孤例。强生、罗氏等巨头都经历过类似阶段当核心专利药进入成熟期时，必须在其利润尚能支撑研发投入时完成投资切换，否则企业会被困在“过度分红与创新空窗”的陷阱。西藏药业此刻的现金储备和稳健分红，恰好提供了这样一个缓冲期。我觉得有意思的，是这家公司选择的不仅是产业资本的扩张，更是一种自我生长机制的重塑。过去，药企靠单一产品驱动；现在，它在尝试“平台化能力”的构建。无论是与晨泰的独家经销协同，还是与锐正的技术绑定，背后体现的是对未来产业生态位的一次再定义。也许五年后再这个时期未必是利润的巅峰，但可能是价值的起点。短期数据的波动掩盖不了一个更深的信号西藏药业正从“产品公司”向“创新系统”转型，从经营一个药，转向经营一次科研生态。这样的转折，往往不喧哗，却足够深远。

财报基因疗法

100 项与盐酸佐利替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14795

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
EGFR 外显子 19 缺失突变型非小细胞肺癌	中国	江苏晨泰医药科技有限公司	2024-11-15
EGFR外显子21替代突变非小细胞肺癌	中国	江苏晨泰医药科技有限公司	2024-11-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
EGFR-T790M 突变非小细胞肺癌	临床3期	中国	江苏晨泰医药科技有限公司	2018-10-29
EGFR-T790M 突变非小细胞肺癌	临床3期	新加坡	江苏晨泰医药科技有限公司	2018-10-29
EGFR-T790M 突变非小细胞肺癌	临床3期	韩国	江苏晨泰医药科技有限公司	2018-10-29
EGFR-T790M 突变非小细胞肺癌	临床3期	中国台湾	江苏晨泰医药科技有限公司	2018-10-29
EGFR突变的非小细胞肺癌	临床3期	中国	阿斯利康投资（中国）有限公司	2018-10-18
EGFR突变的非小细胞肺癌	临床3期	新加坡	阿斯利康投资（中国）有限公司	2018-10-18
EGFR突变的非小细胞肺癌	临床3期	韩国	阿斯利康投资（中国）有限公司	2018-10-18
EGFR突变的非小细胞肺癌	临床3期	中国台湾	阿斯利康投资（中国）有限公司	2018-10-18
软脑膜转移性恶性肿瘤	临床2期	中国	江苏晨泰医药科技有限公司	2026-05-30
EGFR阳性非小细胞肺癌	临床2期	中国	阿斯利康投资（中国）有限公司	2017-10-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03653546 (EVEREST, Pubmed \| Med) 人工标引	临床3期	EGFR突变的非小细胞肺癌一线 EGFR Mutation	439	Zorifertinib	範憲構窪糧襯鹽繭鏇壓(顧積淵糧鬱觸夢蓋衊衊): HR = 0.467 (95% CI, 0.352 ~ 0.619) 更多	积极	2024-10-01
				First-generation EGFR-TKI (gefitinib or erlotinib)
NCT03653546 (ASCO 12023 \| ASCO 22023) 人工标引	临床3期	EGFR突变的非小细胞肺癌一线 EGFR Mutation	439	AZD3759 200 mg	顧衊網壓廠選憲齋膚衊(獵衊範鬱鏇壓積鹽製鹹) = 鹹襯範願廠衊襯醖鬱衊觸衊淵繭窪網膚淵餘願 (餘壓窪簾艱蓋積製鬱淵, 8.2 ~ 9.7) 更多	优效	2023-05-26
				Gefitinib 250 mg or Erlotinib Hydrochloride 150 mg	顧衊網壓廠選憲齋膚衊(獵衊範鬱鏇壓積鹽製鹹) = 艱淵餘鏇蓋齋觸繭蓋夢觸衊淵繭窪網膚淵餘願 (餘壓窪簾艱蓋積製鬱淵, 6.3 ~ 8.0) 更多
NCT03574402 (CTONG1702, ESMO_ELCC2023 \| ESMO_ELCC 12023 \| ESMO_ELCC 22023) 人工标引	临床2期	EGFR突变的非小细胞肺癌一线 EGFR-mutant	30	AZD3759	壓窪積衊夢齋顧選廠鹽(鑰獵觸膚齋衊鹹壓鹹範) = 製鑰艱夢獵網網餘遞繭鏇膚壓鏇範衊願鬱齋窪 (鹹選襯網鹽築壓鹽築遞 ) 更多	积极	2023-03-31
NCT02228369 (BLOOM, Pubmed \| Lancet Respir Med) 人工标引	临床1期	EGFR突变的非小细胞肺癌 EGFR Mutation	67	AZD3759 (dose-escalation)	簾顧糧顧窪鏇簾遞繭憲(選顧壓選襯積齋窪醖觸) = led to treatment discontinuation in one (4%) patient treated with 200 mg twice a day (grade 3 increase of alanine aminotransferase and aspartate aminotransferase) and two (13%) patients given 300 mg twice a day (grade 3 diarrhoea [n=1] and grade 3 skin rash [n=1]). 齋簾鹽襯淵選鑰繭願網 (憲淵顧簾夢構網鹽鑰蓋 ) 更多	积极	2017-11-01
				AZD3759 (dose-expansion)
NCT02228369 (BLOOM, ASCO2017)	临床1期	EGFR阳性非小细胞肺癌 \| 晚期非小细胞肺癌	38	AZD3759 200 mg BID	襯壓構淵範鏇鏇廠繭製(鑰糧積淵膚構觸襯範鬱) = above pEGFR IC90 艱獵淵繭淵鑰醖糧壓觸 (蓋製襯糧積顧鏇鑰膚艱 ) 更多	-	2017-05-30
				AZD3759 300 mg BID
NCT02228369 (BLOOM, ASCO2017)	临床1期	脑膜白血病 \| EGFR突变的非小细胞肺癌	38	AZD3759 200 mg BID	遞齋憲鹽範網獵醖顧齋(膚糧衊襯淵蓋齋糧顧觸) = 67% (12 out of 18) patients had drug-related dose interruption and/or reduction, however, there were no drug-related discontinuations 鹹壓醖製鑰襯壓構壓鹽 (夢憲蓋壓鬱製選簾鑰廠 ) 更多	积极	2017-05-30
				AZD3759 300 mg BID